Open AccessCirculating Soluble Receptor for Advanced Glycation End Products is Inversely Correlated to Oxidized Low-density Lipoproteins in Asymptomatic Subjects
Author(s) -
Kazuhiko Kotani,
Russell Caccavello,
Nobuyuki Taniguchi,
Alejandro Gugliucci
Publication year - 2012
Publication title -
journal of international medical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.421
H-Index - 57
eISSN - 1473-2300
pISSN - 0300-0605
DOI - 10.1177/030006051204000527
Subject(s) - glycation , medicine , asymptomatic , receptor , endocrinology , ldl receptor , biochemistry , lipoprotein , cholesterol , chemistry
Objective: There is growing evidence that circulating soluble receptor for advanced glycation end products (sRAGE) exerts antiatherogenic effects as a decoy receptor that abolishes RAGE signalling. A previous study reported that oxidized low-density lipoprotein (oxLDL) can be one of the RAGE ligands. The present cross-sectional study investigated the clinical association between sRAGE and oxLDL in humans.Methods: Serum levels of the conventional atherosclerotic risk factors, sRAGE and malondialdehyde-modified low-density lipoprotein (MDA-LDL) were analysed in asymptomatic subjects; MDA- LDL was measured as a biomarker of oxLDL.Results: Mean serum levels of sRAGE and MDA-LDL were 1101 ng/l and 57.6 IU/l, respectively, in 33 subjects of mean age 65 years. Simple linear regression analysis showed a significant inverse correlation between sRAGE and MDA-LDL. Stepwise multiple linear regression analysis confirmed MDA-LDL to be independently, significantly and inversely correlated with sRAGE.Conclusions: An independent, significant and inverse correlation was shown to exist between circulating levels of sRAGE and oxLDL (MDA-LDL), which suggests that part of the antiatherosclerotic effects of sRAGE may be related to oxLDL quenching.